Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC
Stopped Slow recruitment due to COVID-19 pandemic and several newly approved treatment options
Conditions
- Hepatocellular Carcinoma
- Sorafenib
Sponsor
University Hospital Tuebingen
Collaborators